TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01216176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anastrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530 (saracatinib)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD0530 (saracatinib)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01807806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Role-playing game
Description: Eligible participants will be invited to engage with a role-playing game for 30 minutes. The role play presents situations where a service member/veteran interacts with family or friends.
Study: NCT01410370

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 6MV-X ray
Description: 3Gy/time, 5 times/week, a total of 10 times

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 6MV-X ray
Description: 3Gy/time, 5 times/week, a total of 10 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: 7.5mg/m2/d, continuous infusion, in parallel with radiotherapy
Study: NCT02267005

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creapure
Description: Patients will be prescribed a creapure supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glucose Tablet
Description: Patients will be prescribed the placebo supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.
Study: NCT06453655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing Process
Description: In the first step of the nursing process, nursing diagnoses NANDA-I and nursing outcomes (NOC) appropriate to the needs of the individual were selected. Immediately afterwards, the baseline measurements of NOCs were made. In the second stage, nursing interventions were determined in line with the selected diagnoses and started to be implemented. Instructions for the implementation of the selected NICs were reminded by phone 3 days before the procedure appointment and compliance with colonoscopy preparation instructions was monitored. In the third stage, after measurement of the NOCs were performed on the day of the procedure. In addition, the BBPS scores calculated by the endoscopist during the procedure were taken from the patient file and recorded in the data collection form and the stages of the nursing process were completed.
Study: NCT00662857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin Inhalation Powder
Description: TI Inhalation Powder, two 15 U cartridges

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin® Inhalation Powder
Description: TI Inhalation Powder, one 30 U cartridge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAA Population
Description: RAA Population: All subjects received a single 10 IU sc injection of insulin lispro.
Study: NCT02427789

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: physical exercise
Study: NCT00989092

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: darbepoetin alfa
Description: Administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: darbepoetin alfa
Description: Administered subcutaneously.
Study: NCT04148014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An Adjunctive Emotion Regulation Skills Training
Description: The adjunctive emotion regulation skills training is delivered in a group format once a week during 5 weeks to young adults with eating disorders together with treatment as usual
Study: NCT00845338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin (BAY79-4998)
Description: Darifenacin 7,5mg tablets once daily for 14 days, darifenacin 7,5mg or 15mg once daily for 14 consecutive days
Study: NCT01061333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedocromil
Description: Nedocromil 4 mg, as metered dose inhaler 1 hour prior to allergen challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Montelukast
Description: Montelukast single 10 mg tablet administered 2 hours prior to allergen challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Mometasone
Description: Mometasone furoate 400 mcg by twisthaler, administered 2 hours prior to allergen challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Mometasone placebo twisthaler, Nedocromil placebo metered dose inhaler, Montelukast placebo tablet
Study: NCT00002864

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: octreotide acetate
Description: Octreotide LAR (SMS 201-995 pa LAR) 90 mg depot injection monthly for 2 years (plus Tamoxifen 20 mg PO daily for 5 years)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate
Description: 20 mg PO for 5 years
Study: NCT01010425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-001 (TransCon PEG hGH)
Description: ACP-001, dose-level 1, s.c., single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-001 (TransCon PEG hGH)
Description: ACP-001, dose-level 2, s.c., single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-001 (TransCon PEG hGH)
Description: ACP-001, dose-level 3, s.c., single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-001 (TransCon PEG hGH)
Description: ACP-001, dose-level 4, s.c., single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, s.c., single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, s.c., single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, s.c., single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, s.c., single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Growth Hormone
Description: Human Growth Hormone, s.c., daily for 7 days
Study: NCT01010425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Growth Hormone
Description: Human Growth Hormone, s.c., daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Growth Hormone
Description: Human Growth Hormone, s.c., daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Growth Hormone
Description: Human Growth Hormone, s.c., daily for 7 days
Study: NCT01599208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: TRANSCRANIAL MAGNETIC STIMULATION

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: TRANSCRANIAL MAGNETIC STIMULATION
Study: NCT00003092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT02153307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable loop recorders system Reveal ICM LINQ®,
Study: NCT05024461

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Salivary test for COVID19
Description: Results of nasopharyngeal and salivary samples taken at the Cayenne hospital and the Caen university center,~* Pre-analytical particularities and analytical particularities~* Cycle threeshold~* Demographic variables~* Clinical variables~* Clinical criteria~* Questionnaire on the perception of the 2 sampling methods
Study: NCT02259842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 34021 FU2 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 34021 FU2 tablet
Description: dose group 4 only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat, high calorie breakfast
Description: only for dose groups 3 and 5
Study: NCT01273610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 250 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Intravenous injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT03149913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SequentPlease OTW paclitaxel coated balloon catheter
Description: PTA with SequentPlease OTW paclitaxel coated balloon catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional uncoated balloon for BTK endovascular therapy
Description: PTA with uncoated balloon for BTK endovascular therapy
Study: NCT03817892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guidance of the External Chest Compression
Description: The CPRmeter® device is positioned on the patient's chest with a disposable adhesive. In the situation of guidance of the External Chest Compression the rescuers have access in real time on the screen to visual feedback on the quality of the External Chest Compression performed and indications of possible corrections to improve the quality of the External Chest Compression . In the case of non-guidance of the External Chest Compression , a mask is position on the screen in order to hide the feedback information.
Study: NCT02422290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single infusion of IV Ketamine, 0.5mg/kg
Study: NCT01172600

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Entonox
Description: Those randomized to Entonox will inhale the gas through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: Those randomized to oxygen will inhale it through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.
Study: NCT03845933

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colon polypectomy
Description: Polyp search and resection will be performed during the withdrawal phase in both groups. Insertion polypectomy will not be performed. All proximal colon polyps will be removed irrespective of their size and appearance.
Study: NCT03817892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guidance of the External Chest Compression
Description: The CPRmeter® device is positioned on the patient's chest with a disposable adhesive. In the situation of guidance of the External Chest Compression the rescuers have access in real time on the screen to visual feedback on the quality of the External Chest Compression performed and indications of possible corrections to improve the quality of the External Chest Compression . In the case of non-guidance of the External Chest Compression , a mask is position on the screen in order to hide the feedback information.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythm of a relay 4 minutes
Description: The duration or rhythm of a relay is the time during which a rescuer performs External Chest Compression before being relayed by another rescuer. This time is 2 minutes in non intervention group according to the current guidelines and 4 minutes in experimental group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythm of a relay 4 minutes
Description: The duration or rhythm of a relay is the time during which a rescuer performs External Chest Compression before being relayed by another rescuer. This time is 2 minutes in non intervention group according to the current guidelines and 4 minutes in experimental group.
Study: NCT04155229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Default settings for opioid prescriptions (acetaminophen/hydrocodone, oxycodone, acetaminophen/oxycodone)
Description: For each of the arms, the investigators modified the default setting for the dispense quantity of study opioids on the electronic medical record settings for discharge prescriptions.~Study drugs include acetaminophen 325mg + hydrocodone 5mg, acetaminophen 325mg + hydrocodone 7.5mg, acetaminophen 325mg + hydrocodone 10mg, oxycodone 5mg, acetaminophen 325mg + oxycodone 5mg, acetaminophen 325mg + oxycodone 10mg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Default settings for opioid prescriptions (acetaminophen/hydrocodone, oxycodone, acetaminophen/oxycodone)
Description: For each of the arms, the investigators modified the default setting for the dispense quantity of study opioids on the electronic medical record settings for discharge prescriptions.~Study drugs include acetaminophen 325mg + hydrocodone 5mg, acetaminophen 325mg + hydrocodone 7.5mg, acetaminophen 325mg + hydrocodone 10mg, oxycodone 5mg, acetaminophen 325mg + oxycodone 5mg, acetaminophen 325mg + oxycodone 10mg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Default settings for opioid prescriptions (acetaminophen/hydrocodone, oxycodone, acetaminophen/oxycodone)
Description: For each of the arms, the investigators modified the default setting for the dispense quantity of study opioids on the electronic medical record settings for discharge prescriptions.~Study drugs include acetaminophen 325mg + hydrocodone 5mg, acetaminophen 325mg + hydrocodone 7.5mg, acetaminophen 325mg + hydrocodone 10mg, oxycodone 5mg, acetaminophen 325mg + oxycodone 5mg, acetaminophen 325mg + oxycodone 10mg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Default settings for opioid prescriptions (acetaminophen/hydrocodone, oxycodone, acetaminophen/oxycodone)
Description: For each of the arms, the investigators modified the default setting for the dispense quantity of study opioids on the electronic medical record settings for discharge prescriptions.~Study drugs include acetaminophen 325mg + hydrocodone 5mg, acetaminophen 325mg + hydrocodone 7.5mg, acetaminophen 325mg + hydrocodone 10mg, oxycodone 5mg, acetaminophen 325mg + oxycodone 5mg, acetaminophen 325mg + oxycodone 10mg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Default settings for opioid prescriptions (acetaminophen/hydrocodone, oxycodone, acetaminophen/oxycodone)
Description: For each of the arms, the investigators modified the default setting for the dispense quantity of study opioids on the electronic medical record settings for discharge prescriptions.~Study drugs include acetaminophen 325mg + hydrocodone 5mg, acetaminophen 325mg + hydrocodone 7.5mg, acetaminophen 325mg + hydrocodone 10mg, oxycodone 5mg, acetaminophen 325mg + oxycodone 5mg, acetaminophen 325mg + oxycodone 10mg.
Study: NCT04392375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine 30 MG
Description: Nifedipine XL is a long-acting medication used to lower blood pressure. The investigators want to learn whether women who receive the study drug will experience fewer severe-range blood pressure readings, and therefore need fewer intravenous (IV) medications to safely lower blood pressure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: At the time of enrollment, patients will be randomized to either the study drug (oral Nifedipine XL 30mg) or identical placebo.
Study: NCT03753295

Intervention type: DIAGNOSTIC_TEST
Intervention: Hand Grip Force
Description: For measuring the grip strength, the subjects will be asked to sit on a chair with their hip joint flexed at 90 degree, and shoulder joint in a neutral position.~The elbow is fixed at 90 degree flexion, forearm in a neutral position, and wrist at 0 to 15 degree radial deviation.~The test will be performed twice, and the higher value between the two measurements will be selected.~The subjects will be allowed a rest time of more than 5 minutes after the first measurement to avoid examiner bias and to decrease physical stress

Intervention type: DIAGNOSTIC_TEST
Intervention: Hand Grip Force
Description: For measuring the grip strength, the subjects will be asked to sit on a chair with their hip joint flexed at 90 degree, and shoulder joint in a neutral position.~The elbow is fixed at 90 degree flexion, forearm in a neutral position, and wrist at 0 to 15 degree radial deviation.~The test will be performed twice, and the higher value between the two measurements will be selected.~The subjects will be allowed a rest time of more than 5 minutes after the first measurement to avoid examiner bias and to decrease physical stress

Intervention type: DIAGNOSTIC_TEST
Intervention: Hand Grip Force
Description: For measuring the grip strength, the subjects will be asked to sit on a chair with their hip joint flexed at 90 degree, and shoulder joint in a neutral position.~The elbow is fixed at 90 degree flexion, forearm in a neutral position, and wrist at 0 to 15 degree radial deviation.~The test will be performed twice, and the higher value between the two measurements will be selected.~The subjects will be allowed a rest time of more than 5 minutes after the first measurement to avoid examiner bias and to decrease physical stress
Study: NCT03974659

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: 1.Patients were given 10 consecutive days bilateral cerebellar VIIa lobules Theta Burst Stimulation which was a special mode of Transcranial magnetic stimulation from one week after surgery Intermittent Theta Burst Stimulation(Positive stimulation) is used in right cerebellar VIIa lobule.Each stimulus had three 50 Hz monopulses, which were repeated every 200 ms. Each stimulation continued for 2 seconds and rested for 8 seconds. The total intervention time was 200s (600 pulses) Continuous Theta Burst Stimulation(Negative stimulation) is used in left cerebellar VIIa lobule,three 50 Hz monopulses in each stimulus, each with an interval of 200 ms, and each intervention lasted 40s (600 pulses).

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: 1.Patients were given 10 consecutive days bilateral cerebellar VIIa lobules Theta Burst Stimulation which was a special mode of Transcranial magnetic stimulation from one week after surgery Intermittent Theta Burst Stimulation(Positive stimulation) is used in right cerebellar VIIa lobule.Each stimulus had three 50 Hz monopulses, which were repeated every 200 ms. Each stimulation continued for 2 seconds and rested for 8 seconds. The total intervention time was 200s (600 pulses) Continuous Theta Burst Stimulation(Negative stimulation) is used in left cerebellar VIIa lobule,three 50 Hz monopulses in each stimulus, each with an interval of 200 ms, and each intervention lasted 40s (600 pulses).
Study: NCT01480947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bio-three
Description: oral Bio-three three times daily for 7 days, Bio-three dosage plan: 1) patients aged 6 years old, 1 tablet t.i.d.; 2) patients aged between 6 and 12 years old, 2 tablets t.i.d.; 3) patients aged 12 years old, 3 tablets t.i.d.

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Bio-three
Description: oral Bio-three three times daily for 7 days, Bio-three dosage plan: 1) patients aged 6 years old, 1 tablet t.i.d.; 2) patients aged between 6 and 12 years old, 2 tablets t.i.d.; 3) patients aged 12 years old, 3 tablets t.i.d.
Study: NCT04429451

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR-PSMA T cells
Description: Infusion of 4SCAR-PSMA T cells at 10\^6 cells/kg body weight via IV
Study: NCT02224209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott EPD systems (Accunet/Emboshield), a balloon, stent
Description: Standard method of endovascular interventional treatment:~Method of stage-1 angioplasty~1. The stent can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield) if distal filter cannot be used, balloon angioplasty can be performed under proximal protection device;~2. Use a balloon with diameter of 2mm × 2cm for stage-1 dilation until angiography shows residual stenosis \<70%.~Method of stage-2:~1. The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);~2. Use an Abbott balloon (diameter of 4 \~ 6mm) for pre-dilation or post-dilation;~3. After the placement of stent, the angioplasty is a success when residual stenosis is \<30%.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a balloon, stent
Description: Routine stenting procedure:~1. The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);~2. Use an Abbott balloon (diameter of 4 \~ 6mm) for pre-dilation or post-dilation;~3. After the placement of stent, the angioplasty is a success when residual stenosis is \<30%.
Study: NCT01292200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: watch DVD and small group discussion
Description: Women in the small-group discussion mode will be called by their community educators to determine possible dates, times, and places for group meetings. The small group sessions will be conducted near the participants' homes. Each small-group will consist of 5-10 participants who will first view a 20-minute video together and then discuss the content of the video as well as their barriers to screening for about 30 minutes. A community educator and an RA at the study site will facilitate the discussion in Chinese languages according to a structured guide.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: watch DVD
Description: Women in the single video mode will receive a cultural video along with an information sheet on local free and low-cost screening programs by mail.
Study: NCT01189864

Intervention type: DRUG
Intervention: Ciprofloxicin or Vigamox or other.
Description: Ciprofloxicin or Vigamox or other to be used qid till epithelialized.

Intervention type: DRUG
Intervention: Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc)
Description: Nonsteroidal (Acular, Voltaren Xibrom, etc) qid up to 5-10 days post-op

Intervention type: DRUG
Intervention: Steroid (FML, Pred Forte, Flarex, etc.)
Description: Steroid (FML, Pred Forte, Flarex, etc.) to be used qid to qd for 1-8 weeks.
Study: NCT00364403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low glycemic load
Description: Provision of foods and dietary counseling to promote a low glycemic load diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low fat diet
Description: Provision of foods and dietary counseling to promote a low fat diet
Study: NCT00734864

Intervention type: DRUG
Group type: OTHER
Intervention: enzyme-inducing anti-epileptic drugs
Description: Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).

Intervention type: DRUG
Group type: OTHER
Intervention: enzyme-inducing anti-epileptic drugs
Description: Subjects NOT taking EIAEDs (CYP-3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).